Key result
High circulating EPA is linked to ~37% lower odds of elevated IL-1β in acute MI.
Why the study?
The relationship between plasma eicosapentaenoic acid (EPA), EPA/DHA ratio, and inflammatory biomarkers in patients with acute myocardial infarction was not well characterized.
Observational (n=575)
No
Answers are grounded in this paper and cite their sources.
In patients with acute myocardial infarction, higher circulating levels of EPA and a higher EPA/DHA ratio are significantly associated with lower levels of inflammatory biomarkers such as IL-1β and hs-CRP.
Omega-3 fatty acids (n-3 FAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have emerging protective roles in cardiovascular (CV) diseases.1 The Reduction of Cardiovascular Events with Icosapent Ethyl—Intervention Trial (REDUCE-IT) showed reduction, by 25%, in the risk of ischaemic events and CV death compared with placebo of high-dose icosapent ethyl (IPE) in statin-treated adults at high CV risk with elevated triglycerides.2 Nevertheless, several issues regarding the efficacy of n-3 FAs are the subject of lively debate. The residual risk reduction with IPE goes beyond triglyceride lowering, suggesting the involvement of a broad panel of pleiotropic effects of EPA.1 While other clinical trials with purified EPA also found positive results on major coronary events,3 mixed EPA/docosahexaenoic acid (DHA) formulations showed less effectiveness in large outcomes trials, despite similar degrees of triglyceride lowering.4,5 Finally, mineral oil used as placebo in the control group of REDUCE-IT was associated with an increase in inflammation, whereas IPE-treated patients displayed only moderate improvement in biomarkers. These data underscore the need for more extensive information on the relationship between EPA, EPA/DHA ratio, and inflammatory biomarkers in high-risk patients.6 The Relation between OMega-3 fatty acids and Inflammation in patients with acute myocardial infarction (OM3I) prospective study aimed to analyse the relationship between plasma EPA levels and inflammation in patients with acute myocardial infarction (MI). From 1 January 2021 to 30 May 2022, consecutive patients admitted <24 h after symptom onset to the coronary care unit of the Dijon University Hospital for type 1 MI were included. Patients with chronic inflammatory disease or on anti-inflammatory drugs were excluded. The ethics committee approved the protocol registered on Health Data Hub (https://health-data-hub.fr, #F20210727150424). This study conforms to the principles outlined in the Declaration of Helsinki. Patients provided written informed consent prior to inclusion. Heparinized blood samples were harvested on admission and centrifuged <1 h after collection. Plasma interleukin-1β (IL-1β) levels were determined using a high-sensitivity enzyme-linked immunosorbent assay (ThermoFisher Scientific) with a limit of quantification (LOQ) of 0.05 pg/mL. Plasma FAs were quantified by gas chromatography–mass spectrometry. Other clinical biological parameters, including high-sensitivity C-reactive protein (hs-CRP), were measured at the automated biochemistry laboratory of the Dijon University Hospital. Amongst included 575 patients, 217 (38%) displayed IL-1β levels above LOQ. Patients with elevated IL-1β (>0.05 pg/mL) were 3 years older than patients without detectable IL-1β and had a similar burden of most risk factors, whereas history of coronary artery disease and chronic kidney disease (CKD) was more common (Figure 1A). Patients with IL-1β > 0.05 pg/mL displayed higher hs-CRP levels, and there was a positive correlation between IL-1β and hs-CRP levels in these patients (Figure 1A). EPA and DHA represented 0.725 [95% confidence interval (CI), 0.672–0.756] and 1.65% (95% CI, 1.60–1.71) respectively, of total FAs. EPA levels were lower in males and in patients with diabetes, hypercholesterolaemia, and current smoking (Figure 1B). EPA levels correlated positively with LDL and HDL-cholesterol and negatively with triglycerides (Figure 1B). EPA/DHA ratio was lower in patients with diabetes, CKD, and history of atrial fibrillation. EPA/DHA correlated positively with LDL and HDL-cholesterol and negatively with age (Figure 1B). (A) Clinical and biological characteristics according to the interleukin-1β (IL-1β) value (≤ or >0.05 pg/mL). (B) Relationship between eicosapentaenoic acid (EPA) and EPA/docosahexaenoic acid (DHA) ratio with clinical and biological characteristics. BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; HDL-C, high-density lipoprotein cholesterol; STEMI, ST-segment elevation myocardial infarction. (C) Correlation between IL-1β and EPA levels. (D) Violin plots of EPA, DHA levels, and EPA/DHA ratio in patients with IL-1β ≤ or >0.05 pg/mL. (E and F) Forest plots showing odds ratio values and 95% confidence intervals for multivariable logistic regression analysis of IL-1β and clinic-biological variables. Dichotomous variables are expressed as n (%) and continuous variables as median (interquartile range). The χ2 test or Fisher’s test was used for dichotomous data. A Kolmogorov–Smirnov test was used to test the normality of variables. Non-normally distributed variables were log-transformed when needed. The Mann−Whitney test or Student’s t-test was used to compare continuous data, as appropriate. Spearman’s correlation analyses were performed (r). Multivariable logistic regression models were built to estimate IL-1β levels, based on significant variables in univariate analysis, with an inclusion threshold at 10%. Variable selection was stepwise. Missing data were at random and were omitted. SPSS version 12.0.1 (IBM Inc., Armonk, NY, USA) was used for all the tests. Patients with IL-1β > 0.05 pg/mL had lower EPA levels than those with IL-1β ≤ 0.05 pg/mL (0.666% vs. 0.755%; P < 0.01), and among these patients, there was a negative correlation between IL-1β and EPA levels (r = −0.159; P = 0.0193) (Figure 1C–D). EPA also negatively correlated with hs-CRP levels (r = −0.109; P = 0.009) (Figure 1B). Interestingly, there were no differences in DHA levels according to IL-1β levels (Figure 1D) and no association between DHA and hs-CRP levels (r = −0.012; P = 0.768). Moreover, EPA/DHA ratio was significantly lower in patients with higher IL-1β levels (0.410 vs. 0.460; P < 0.001) (Figure 1D) and EPA/DHA ratio correlated negatively with hs-CRP levels (Figure 1B). In multivariable analysis, high level of EPA was a powerful estimate of IL-1β (odds ratio, 0.631; 95% CI, 0.426–0.935), beyond CAD (Figure 1E), while elevated EPA/DHA showed only a trend towards IL-1β estimation [odds ratio, 0.736 (95% CI, 0.449–1.085)] (Figure 1F). Introduction of aspirin or statins therapies as covariates in the multivariate analysis did not affect the capacity of EPA to estimate elevated IL-1β levels (data not shown). While there is considerable variation in inter-assays, our IL-1β measurements were in line with recent studies6 and consistent with hs-CRP levels. We also noted a consistent negative correlation between EPA, EPA/DHA ratios, and hs-CRP, similar to what we observed with IL-1β, underscoring the reliability of our results. Although our data are cross-sectional during the course of MI, elevated inflammatory markers of the IL-1β-IL-6-CRP axis measured upon admission, in the early phase of MI, have been robustly associated with a poor prognosis.7,8 Accordingly, in the present study, high IL-1β levels were associated with higher frequency of left ventricular ejection fraction (LVEF) < 40% and higher SYNTAX scores. This work points towards an unexpected differential impact of EPA and DHA on inflammation in the setting of an acute MI. Remarkably, and despite the strong positive correlation between EPA and DHA in acute MI patients, we robustly showed that not only EPA but also the EPA/DHA ratio are negatively associated with inflammation biomarkers, while no significant association is found for DHA. A wide range of underlying mechanisms have been proposed to explain the beneficial effects of n-3 FAs on CV system, including anti-inflammatory, antioxidant, antithrombotic, and membrane fluidity-modulating properties.1,9 n-3 FAs give rise to a wide range of specialized pro-resolving lipid mediators that reduce inflammation in different tissues and vascular beds, exerting atheroprotective effects. Since endogenous formations of hydroxy and epoxy FA metabolites generally correlate with the abundance of their metabolic PUFA precursors, elevated EPA levels could lead to an enhanced production of EPA-derived anti-inflammatory mediators such as 18-hydroxyeicosapentaenoic acid (18-HEPE).10 Additionally, EPA has demonstrated its ability to dampen inflammation by inhibiting the NLRP3 [nucleotide-binding domain leucin-rich repeat (LRR) and pyrin-containing receptor 3] inflammasome, thereby reducing IL-1β release. Lastly, within n-3 FAs, and beyond DHA, the chemical structure of EPA characterized by an optimal combination of chain length and degree of unsaturation endows it with potent antioxidant properties, conferring differential vasculo-protective effects.1 Our study has shown for the first time that, in patients with acute MI, circulating levels of EPA and the EPA/DHA ratio are negatively associated with inflammatory biomarkers from the IL-1β/CRP axis. The translation of these relationships in EPA-supplemented patients remains speculative. Being an observational, prospective study, causality cannot be proven, and our observations require external validation due to the single-centre design. However, if confirmed in stable CAD patients, our findings may contribute to the understanding of the emerging cardioprotective effects of n-3 FAs in high-risk patients. The authors thank Maïlis Saint Jalmes, Jessica Massenot, and Etienne Baudouin for their help with data collection and Hélène Choubley and Victoria Bergas from the lipidomic platform. Sophie Rushton-Smith (MedLink Healthcare Communications) provided editorial support, funded by the authors. This work was supported by the CHU Dijon Bourgogne, Association de Cardiologie de Bourgogne, and Fédération Française de Cardiologie; by grants from the ARS de Bourgogne Franche-Comté and Conseil Régional de Bourgogne Franche-Comté; and by a French Government, Agence Nationale de la Recherche, grant managed under the programme ‘Investissements d’Avenir’ with reference ANR-11-LABX-0021. All data are available from the corresponding authors upon request.
No takes yet. Share an insight, caveat, or question.
Masson et al. (2024) conducted an observational in Acute myocardial infarction (n=575). Plasma eicosapentaenoic acid (EPA) levels vs. Lower EPA levels was evaluated on Elevated interleukin-1β (IL-1β) levels (>0.05 pg/mL) (OR 0.631, 95% CI 0.426-0.935). High circulating levels of EPA were inversely associated with elevated IL-1β levels in patients with acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: